Inorganic compound. Accumulates in bone tissue. Not metabolised.

(To be edited, initial data ST OCT 04) Biphosphonate with osteoclast inhibiting properties. Used in tumor-induced hypercalcemia. Intravenously administered ibandronate is mainly bound to bone tissue, the remaining part being excreted by the kidneys in unchanged form.

Uneventful use reported in 1 patient with acute porphyria.